Compare IONQ Inc (IONQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Twist Bioscience Corp — how do they compare? IONQ Inc trades at $35.65 (market cap $12.78B), while Twist Bioscience Corp trades at $94.13 (market cap $5.45B). The key difference: IONQ Inc is far larger — about 2.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| IONQ | TWST | |
|---|---|---|
Market Cap | $12.78B | $5.45B |
Sector | Technology | Health |
52-Week High | $82.09 | $102.88 |
52-Week Low | $26.59 | $24.16 |
Enterprise Value | $10.78B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.24, down 1.55% with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth projections from $130M in 2025 to $187M in 2026, but remains unprofitable with a net loss of $510M in 2025. Analyst consensus is split with a $73.75 price target representing 115% upside potential. Recent news highlights IonQ's leadership in quantum computing platform development and government validation.
The stock offers significant upside potential based on analyst targets but faces execution risks in achieving profitability. High valuation multiples (P/E 89.18, P/S 58.73) reflect growth expectations, while negative cash flow from operations and competitive threats in quantum computing present substantial risks for investors.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
